The English name and global market situation of axitinib/axitinib

Axitinib/Axitinib , known in English as Axitinib, is an oral small molecule tyrosine kinase inhibitor (TKI) developed by Pfizer. It is mainly used to treat advanced renal cell carcinoma (RCC) . Axitinib As a second-generation VEGFR (vascular endothelial growth factor receptor) inhibitor, axitinib has highly selective and potent inhibitory effects on VEGFR-1, -2 and -3, and can block tumor angiogenesis. It is one of the important drugs in the current targeted therapy of renal cancer.

In 2012, the U.S. Food and Drug Administration (FDA) approved axitinib for patients with advanced renal cell carcinoma who have progressed after previously receiving a systemic treatment. Since then, it has also been approved in the European Union, Japan, Canada and other countries. In multiple international clinical trials, axitinib has shown good efficacy and tolerability, especially showing high progression-free survival (PFS) in patients who have failed treatment with sorafenib or interferon.

In the global market, axitinib has become one of the standard second-line regimens for the treatment of advanced renal cancer, and is being studied for use in first-line treatment regimens combined with immune checkpoint inhibitors (such asPD-1/PD-L1 antibodies). Pfizer has a supply chain system in multiple countries to ensure widespread accessibility of the drug. In recent years, as its efficacy has been continuously clinically verified, its use in the Chinese market has gradually increased.

In addition to advanced renal cancer, researchers are also exploring its potential role in other blood vessel-dependent tumors, such as liver cancer, thyroid cancer, etc., to broaden its application scope. Axitinib has extensive global application value in the field of targeted tumor therapy, and its market potential will continue to expand in the future.

Reference materials:https://en.wikipedia.org/wiki/Axitinib